Boehringer Ingelheim's survodutide produced up to 13.1% mean weight loss at 76 weeks in adults with obesity and type 2 diabetes, according to Phase 3 SYNCHRONIZE-2 data presented at EASD 2026 on October 1 and published the same day in the New England Journal of Medicine. Placebo lost 3.1%. HbA1c fell by up to 1.21 points from a 7.4% baseline.
The second number to know is 18%. That is the share of survodutide participants who stopped treatment because of gastrointestinal side effects, against 1.2% on placebo. It is the figure that pulls the stricter treatment-regimen result down to 9.8%, and it is the main open question Boehringer now has to answer before filing.
Research-context information only. Survodutide is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and company disclosures. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
What SYNCHRONIZE-2 Reported
SYNCHRONIZE-2 was a 76-week, double-blind, placebo-controlled Phase 3 trial. Wharton et al. (NEJM, 2026; PMID 42820639) randomized 752 adults with type 2 diabetes and a BMI of 27 or higher 1:1:1 to weekly subcutaneous survodutide 3.6 mg, survodutide 6.0 mg, or placebo. Mean age was 55.7 years and mean BMI 36.5. Both co-primary endpoints, percent weight change and the share reaching at least 5% loss, were met.
Boehringer's press release led with the efficacy estimand, which estimates the effect in people who stayed on treatment. The NEJM abstract led with the treatment-regimen estimand, which counts everyone randomized regardless of whether they stopped. Both are real, and the gap between them is the story.
| Week 76 outcome | Survodutide 3.6 mg | Survodutide 6.0 mg | Placebo |
|---|---|---|---|
| Weight change, efficacy estimand | -10.4% | -13.1% | -3.1% |
| Weight change, treatment-regimen estimand | -8.2% | -9.8% | -3.9% |
| Reached at least 5% loss (treatment-regimen) | 57.6% | 64.5% | 35.1% |
| HbA1c change from 7.4% (treatment-regimen) | -0.9 pts | -0.8 pts | -0.2 pts |
| GI adverse events | 72.8% | 77.7% | 38.6% |
| Stopped due to GI events | 18.0% | 17.9% | 1.2% |
| Serious adverse events | 9.2% | 8.4% | 10.8% |
Sources: Wharton et al., NEJM 2026 (PMID 42820639); Boehringer Ingelheim release, October 1, 2026; Healio EASD coverage, October 1, 2026.
Boehringer's release added efficacy-estimand secondary results: up to 79.3% reached at least 5% weight loss (versus 32.7% on placebo), HbA1c fell by up to 1.21 points, waist circumference shrank by up to 11.1 cm (versus 3.5 cm), and up to 29.5% of participants returned to normoglycemia, an HbA1c below 5.7%, versus 4.0% on placebo.
Coordinating investigator Dr. Sean Wharton told Healio it was "an impressive amount of weight loss in patients living with type 2 diabetes," noting that this population typically loses less weight than people without diabetes.
Three Things the Numbers Show
The 6.0 mg dose barely separated from 3.6 mg. On the treatment-regimen estimand, the higher dose added only 1.6 points of weight loss. On HbA1c the two doses were essentially tied, at -0.9 and -0.8 points. Higher doses meant a larger GI burden without a matching glucose benefit. That is relevant to how future label doses get chosen.
The discontinuation rate is high for the class. About 1 in 6 survodutide participants left over GI events. Boehringer said most discontinuations happened during dose escalation and that newer trials, including SYNCHRONIZE-START, use more flexible titration. The survodutide dosing guide covers the titration schedules documented across the trial program. Whether slower escalation brings dropouts down is the next data point to watch.
The diabetes penalty showed up as expected. In SYNCHRONIZE-1, which excluded diabetes, Boehringer reported 16.6% weight loss on the efficacy estimand at 76 weeks. The drop to 13.1% here matches what other incretin drugs reported when they moved from non-diabetic to diabetic populations. Our SYNCHRONIZE-1 breakdown covers the first Phase 3 readout.
How It Compares in Diabetes Trials
Diabetes trials are the fairer benchmark, since every drug loses ground in this population. No head-to-head trial exists, so the figures below come from separate studies with different durations and designs. Survodutide and retatrutide are investigational; semaglutide and tirzepatide are active ingredients in FDA-approved products.
| Compound | Mechanism | Diabetes-population Phase 3 weight loss | Trial |
|---|---|---|---|
| Semaglutide 2.4 mg | GLP-1 | 9.6% at 68 weeks | STEP 2 (Davies et al., Lancet 2021) |
| Survodutide 3.6-6.0 mg | GLP-1 + glucagon | 8.2-9.8% (TR) / 10.4-13.1% (efficacy) at 76 weeks | SYNCHRONIZE-2 (Wharton et al., NEJM 2026) |
| Tirzepatide 10-15 mg | GIP + GLP-1 | 12.8-14.7% at 72 weeks | SURMOUNT-2 (Garvey et al., Lancet 2023) |
| Retatrutide 12 mg | GIP + GLP-1 + glucagon | 20.8% at 80 weeks | TRIUMPH-2 (Lilly topline, July 2026) |
STEP 2 (PMID 33667417) reported semaglutide 2.4 mg at 9.6% versus 3.4% on placebo. SURMOUNT-2 (PMID 37385275) reported tirzepatide's 12.8% and 14.7% under its treatment-regimen estimand. On the comparable estimand, survodutide's 9.8% sits beside semaglutide and below tirzepatide. Retatrutide's TRIUMPH-2 topline remains the high mark among compounds that include a glucagon component.
On weight alone, then, survodutide does not lead in diabetes. Boehringer's case rests elsewhere: the glucagon arm's liver activity. The MASH Phase 2 data are summarized in our survodutide benefits review, and the LIVERAGE Phase 3 program in MASH fibrosis and cirrhosis is the readout that decides whether survodutide earns a distinct niche.
Research-Use Supply and Verification
The SYNCHRONIZE-2 data change nothing about survodutide's legal status. It is not FDA-approved and has no announced US filing date. It appears on a small number of research peptide catalogs as research-use-only material, and supply is thinner than for retatrutide or tirzepatide. The trial results above come from clinical-grade drug supplied under trial conditions and do not describe research-grade material.
Two practical points follow from the trial:
- Supply is thin, so verification carries more weight. Survodutide is a 39-amino-acid lipidated peptide, harder to synthesize than short peptides like BPC-157. Lot-specific third-party HPLC and mass-spec results are how buyers of research material verify identity and purity; the COA verification guide covers what to check.
- Price per milligram varies widely. The survodutide buying guide tracks current per-vial pricing, COA status and coupon codes. Live listings are on best survodutide vendors.
All listed products are sold for research use only.
